The AmplideX® suite of products is designed to solve unmet testing needs in inherited genetic disorders. The technology overcame a 20-year challenge by reliably amplifying the FMR1 gene. This allowed researchers to gain a deeper understanding of fragile X syndrome, the most common known inherited cause of intellectual disability and autism.
The AmplideX® C9orf72 Kit is a tool for the reliable amplification of the hexanucleotide CG repeat in the C9orf72 gene associated with amyotrophic lateral sclerosis and frontotemporal dementia.
- Directly on 1 FFPE tissue section
- Detecting 18 relevant mutations
Being the third¹ liquid biopsy test for Biocartis, the newly launched assay, Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only), also marks an important milestone in the partnership with the leading science and technology company Merck².
A revolution in liquid biopsy cancer research.
Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients
Biocartis is pleased to announce the publication of an important study  by Prof. Dr. Bart Neyns from the University Hospital in Brussels (Belgium) in the clinical oncology journal The Lancet Oncology: ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’.
Get connected and enjoy the advantages of Idylla Explore, a web-based application that allows you to analyze your data by providing:
Idylla™ offers complete CE-marked RAS testing for metastatic CRC.
Biocartis, an innovative molecular diagnostics company, today announces the launch of its second liquid biopsy assay, the Idylla™ ctKRAS Mutation Assay (Research Use Only, RUO), which was developed in partnership with the leading science and technology company Merck1 on Biocartis’ molecular diagnostics platform Idylla™.